BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Investigation of Mass Balance of the Test Drug and Major Metabolites
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2015-12-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 7
- Registration Number
- NCT00432302
Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia
Phase 3
Completed
- Conditions
- Pneumonia
- Interventions
- First Posted Date
- 2007-02-06
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 738
- Registration Number
- NCT00431678
Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension
Phase 2
Completed
- Conditions
- PostmenopausePre-HypertensionHypertension
- Interventions
- Drug: Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)Drug: SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 92
- Registration Number
- NCT00420342
Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension
- First Posted Date
- 2006-12-21
- Last Posted Date
- 2009-05-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 63
- Registration Number
- NCT00414687
Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2010-09-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1493
- Registration Number
- NCT00410306
Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection
Phase 3
Completed
- Conditions
- AbscessWound InfectionUlcerDiabetic Foot
- Interventions
- Drug: Moxifloxacin (Avelox, BAY12-8039)Drug: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2014-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 813
- Registration Number
- NCT00402727
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
Phase 2
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 613
- Registration Number
- NCT00402467
Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
Phase 2
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2009-05-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 726
- Registration Number
- NCT00398905
Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
Phase 2
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2006-11-07
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 877
- Registration Number
- NCT00396786
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients
Phase 3
Completed
- Conditions
- Vascular Diseases
- Interventions
- Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)Drug: Gadopentate dimeglumine (Magnevist, BAY86-4882)
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 83
- Registration Number
- NCT00395733
© Copyright 2025. All Rights Reserved by MedPath